|1.||Beygui, Farzin: 3 articles (05/2015 - 10/2010)|
|2.||Manrique, Alain: 2 articles (05/2015 - 01/2015)|
|3.||Rouet, René: 2 articles (05/2015 - 01/2015)|
|4.||Alexandre, Joachim: 2 articles (05/2015 - 01/2015)|
|5.||Milliez, Paul: 2 articles (05/2015 - 01/2015)|
|6.||Vanhoutte, Paul M: 2 articles (01/2005 - 06/2004)|
|7.||Bos, Romain: 2 articles (01/2005 - 06/2004)|
|8.||Médiani, Odile: 2 articles (01/2005 - 06/2004)|
|9.||Mougenot, Nathalie: 2 articles (01/2005 - 06/2004)|
|10.||Lechat, Philippe: 2 articles (01/2005 - 06/2004)|
01/28/1986 - "[Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites]."
01/01/1994 - "Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites."
11/01/2006 - "Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis."
06/01/1991 - "In a randomized double-blind trial we compared the effects of torasemide, a new loop diuretic, and furosemide in nonazotemic cirrhotic patients with ascites during a 3-day period in association with potassium canrenoate (200 mg/day) administration. "
03/01/2001 - "As expected from the aldosterone independence of Na(+) retention in PAN nephrotic rats, blockade of aldosterone receptor by potassium canrenoate did not alter urinary Na(+) excretion, Na(+) balance, or ascites formation in PAN nephrotic rats."
|2.||Hypertension (High Blood Pressure)
04/01/2012 - "Potassium canrenoate (PC) is a synthetic steroid and is used in the treatment of hypertension. "
01/01/1995 - "Potassium canrenoate (K-Can) prevents hypertension in Milan hypertensive strain (MHS) but not in spontaneously hypertensive rats (SHR). "
01/01/1995 - "Recognition of markers of response to potassium-canrenoate in essential hypertension."
06/01/1976 - "The development of hypertension in "adrenal enucleation" rats was prevented by treatment with SC 14266 and the drug did not significantly affect the blood pressure in either "unilateral nephrectomy" or "normal" rats. "
04/07/1983 - "[Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension]."
01/01/1977 - "In 16 patients with critical condition due to severe heart failure associated with digitalis toxicity, the effects of potassium canrenoate (AldactoneR) administered intravenously were studied. "
01/01/1977 - "The effect of intravenous potassium canrenoate in patients with severe heart failure and digitalis toxicity."
10/01/2010 - "ALBATROSS is a nationwide, multicenter, open-labeled, randomized trial designed to assess the superiority of aldosterone blockade by a 200-mg intravenous bolus of potassium canrenoate followed by a daily 25-mg dose of spirinolactone for 6 months, on top of standard therapy compared to standard therapy alone among 1,600 patients admitted for ST-segment elevation or high risk non-ST-segment elevation acute AMI -TIMI score ≥3-within 72 hours after symptom onset regardless of heart failure and treatment strategy. "
01/01/2008 - "Male lean spontaneously hypertensive heart failure (SHHF) rats (40 wk) were treated for 8 wk by sc infusions of low (0.24 mg/kg.d) or high (1.2 mg/kg.d) doses of R- or S-fadrozole or by potassium canrenoate via drinking water (7.5 mg/kg.d). "
08/01/1983 - "Aldactone (200 mg potassium canrenoate i.v.) was given in a single dose as the sole drug to 30 patients with congestive heart failure (CHF). "
|4.||Hyperaldosteronism (Conn Syndrome)
10/01/2007 - "Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate."
03/01/2005 - "These data are consistent with possible regression of idiopathic primary hyperaldosteronism after long-term therapy with potassium canrenoate, or in alternative to a persistent effect of potassium canrenoate, on aldosterone synthesis."
03/01/2005 - "We conclude that long-term therapy with the aldosterone-receptor blocker, potassium canrenoate, can normalize the aldo/PRA ratio in many cases of idiopathic primary hyperaldosteronism after one-month withdrawal of the drug. "
03/01/2005 - "We have re-evaluated 15 patients with idiopathic primary aldosteronism one month after withdrawal of therapy with aldosterone-receptor antagonist potassium canrenoate. "
06/01/1983 - "For pharmacologic screening to identify hyperaldosteronism in patients after renal transplantation, spironolactone (Soludactone, Searle) was administered intravenously in 12 subjects (mean dose 1.2 g in the course of 3 days). "
04/01/1984 - "One thousand consecutive patients admitted for myocardial infarction were given an antialdosterone agent systematically (intravenous potassium canrenoate , 600 mg daily for 5 days). "
01/01/1980 - "Systolic time intervals (TS) were determined before and after intravenous injection of 400 mg of Potassium-Canrenoate (CK) in 33 patients 30 days after acute myocardial infarction, in order to evaluate the inotropic effect of this drug. "
09/01/1979 - "[Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction]."
05/01/2015 - "Recent clinical studies have reported the potential benefit of an early mineralocorticoid receptor (MR) blockade with potassium canrenoate (PC) on ventricular arrhythmias (VAs) occurrence in patients experiencing an ST-segment elevation myocardial infarction (STEMI). "
01/01/1977 - "Following a description of hemodynamic and metabolic effects of an acute myocardial infarction, indications for a therapy with furosemide, isosorbiddinitrate, digitalis, canrenoate-potassium, and dopamine and the results thereof are discussed. "
|9.||Mineralocorticoid Receptors (Mineralocorticoid Receptor)
|2.||Gynecologic Surgical Procedures (Gynecologic Surgery)